# BrUOG 390: Neoadjuvant Treatment With Talazoparib

> **NCT04598321** · PHASE1 · TERMINATED · sponsor: **Brown University** · enrollment: 1 (actual)

## Conditions studied

- BRCA1 Mutation
- BRCA2 Mutation
- Ovarian Cancer
- Fallopian Tube Cancer
- High Grade Serous Carcinoma

## Interventions

- **DRUG:** Talazoparib Oral Capsule

## Key facts

- **NCT ID:** NCT04598321
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-29
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-12-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** termination of research grant agreement
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04598321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04598321, "BrUOG 390: Neoadjuvant Treatment With Talazoparib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04598321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*